BioNTech plans to produce vaccines in Singapore
May 12, 2021: -On Monday, BioNTech announced it would set up its Southeast Asia headquarters in Singapore and build a manufacturing facility in the city-state to produce its messenger RNA vaccines and different medicines to treat infectious diseases and cancer.
AstraZeneca to work on COVID-19 vaccine with Russia’s Sputnik V
AstraZeneca to work on COVID-19 vaccine with Russia’s Sputnik V December 13, 2020 British pharmaceutical giant AstraZeneca said Friday it would soon start work with Russia’s Gamaleya Institute to investigate whether their two coronavirus vaccine candidates could be successfully combined. It comes after the developers of the Sputnik V Covid-19 vaccine approached AstraZeneca via Twitter last month to ask if they should try combining both to boost vaccine efficacy. “Being able to combine different COVID-19 vaccines may help improve protection and improve vaccine accessibility. This is why it is important to explore different vaccine combinations to help make immunization programs more flexible, by allowing physicians greater choice at the time of administering vaccines,” AstraZeneca said in a statement. AstraZeneca’s Covid-19 vaccine, produced in collaboration with the University of Oxford, is one of several seeking to secure approval from medicine regulators amid rising hopes that a mass vaccination campaign could help end the pandemic. To date, more than 69 million people have contracted the coronavirus worldwide, with 1.58 million related deaths, according to data compiled by Johns Hopkins University. “We welcome the beginning of this new stage of cooperation between vaccine producers. We are determined to develop this partnership in the future and to start joint production after the new vaccine demonstrates its efficacy in the course of clinical trials,” Dmitriev said. Top News
AstraZeneca sees 2022 growth as dividend increases
February 11, 2022: -On Thursday, AstraZeneca forecast higher 2022 sales and raised its annualized dividend after the drugmaker posted better-than-expected fourth-quarter profit as it gets a lift from its Covid-19 antibody treatment and cancer drugs.
AstraZeneca invests in the self-amplifying RNA technology
September 24, 2021: -On Thursday, AstraZeneca struck a deal with the firm behind Imperial College London’s experimental Covid-19 vaccine to create and sell drugs based on its self-amplifying RNA technology platform in other disease areas.
Electronic Medical Record – Digital Approach To Healthcare
Electronic Medical Records provide a wide range of information. Physical history and the physical order of the patient. A detailed update about the patient’s insurance and also demographic data.
Digital Health – Ruling the Healthcare Industry
Being on par with the digital era is possible only by adopting emerging technology. To adapt, one must be ready to let go of the traditional business methodology.
Clinical trials are changing – for good
In healthcare, the world of clinical trials seems to be up for some big moves – and permanent ones at that, HRI predicted. “In the face of a pandemic that seized nearly everyone, from patients to clinical trial coordinators, to stay home, at least momentarily, pharmaceutical and life sciences companies have been challenging: How much can be done remotely?” the report read. “Quite a bit, it turns out
